119 related articles for article (PubMed ID: 12466391)
1. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma.
Kloos RT; Duvuuri V; Jhiang SM; Cahill KV; Foster JA; Burns JA
J Clin Endocrinol Metab; 2002 Dec; 87(12):5817-20. PubMed ID: 12466391
[TBL] [Abstract][Full Text] [Related]
2. [Lacrimal drainage system obstruction associated to radioactive iodine therapy for thyroid carcinoma].
Fonseca FL; Lunardelli P; Matayoshi S
Arq Bras Oftalmol; 2012; 75(2):97-100. PubMed ID: 22760799
[TBL] [Abstract][Full Text] [Related]
3. Relationship between radioactive iodine therapy for thyroid carcinoma and nasolacrimal drainage system obstruction.
Cetinkaya A; Kersten RC
Ophthalmic Plast Reconstr Surg; 2007; 23(6):496. PubMed ID: 18030131
[No Abstract] [Full Text] [Related]
4. Salivary gland dysfunction and nasolacrimal duct obstruction: stenotic changes following I-131 therapy.
Savage MW; Sobel RK; Hoffman HT; Carter KD; Finkelstein MW; Shriver EM
Ophthalmic Plast Reconstr Surg; 2015; 31(3):e50-2. PubMed ID: 24836449
[TBL] [Abstract][Full Text] [Related]
5. Visualization of nasolacrimal drainage system after radioiodine therapy in patients with thyroid cancer.
Sakahara H; Yamashita S; Suzuki K; Imai M; Kosugi T
Ann Nucl Med; 2007 Nov; 21(9):525-7. PubMed ID: 18030585
[TBL] [Abstract][Full Text] [Related]
6. Nasolacrimal obstruction secondary to I(131) therapy.
Burns JA; Morgenstern KE; Cahill KV; Foster JA; Jhiang SM; Kloos RT
Ophthalmic Plast Reconstr Surg; 2004 Mar; 20(2):126-9. PubMed ID: 15083081
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic dacryocystorhinostomy following radioactive iodine thyroid ablation.
Van Tassel SH; Segal KL; Hsu NM; Kacker A; Lelli GJ
Orbit; 2017 Apr; 36(2):59-63. PubMed ID: 28388347
[TBL] [Abstract][Full Text] [Related]
8. Nasolacrimal duct obstruction associated with radioactive iodine therapy for thyroid carcinoma.
Shepler TR; Sherman SI; Faustina MM; Busaidy NL; Ahmadi MA; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2003 Nov; 19(6):479-81. PubMed ID: 14625496
[TBL] [Abstract][Full Text] [Related]
9. Nasolacrimal duct obstruction as a complication of iodine-131 therapy in patients with thyroid cancer.
Fard-Esfahani A; Farzanefar S; Fallahi B; Beiki D; Saghari M; Emami-Ardekani A; Majdi M; Eftekhari M
Nucl Med Commun; 2012 Oct; 33(10):1077-80. PubMed ID: 22825036
[TBL] [Abstract][Full Text] [Related]
10. Epiphora after radioactive iodine ablation for thyroid cancer.
Sun GE; Hatipoglu B
Thyroid; 2013 Feb; 23(2):243-5. PubMed ID: 22946448
[TBL] [Abstract][Full Text] [Related]
11. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients.
Morgenstern KE; Vadysirisack DD; Zhang Z; Cahill KV; Foster JA; Burns JA; Kloos RT; Jhiang SM
Ophthalmic Plast Reconstr Surg; 2005 Sep; 21(5):337-44. PubMed ID: 16234694
[TBL] [Abstract][Full Text] [Related]
12. Nasolacrimal drainage obstruction after radioiodine therapy: case report and a review of the literature.
Brockmann H; Wilhelm K; Joe A; Palmedo H; Biersack HJ
Clin Nucl Med; 2005 Aug; 30(8):543-5. PubMed ID: 16024949
[TBL] [Abstract][Full Text] [Related]
13. Surgical Risk Prediction for Nasolacrimal Duct Obstruction in Radioactive Iodine-Treated Thyroid Cancer: A Nationwide Cohort Study.
Lee JY; Woo KI
Thyroid; 2022 May; 32(5):544-551. PubMed ID: 34894720
[No Abstract] [Full Text] [Related]
14. Factors Associated With Radioactive Iodine Therapy-Acquired Nasolacrimal Duct Obstruction.
Lee IT; Chen W; Chen Q; Cole HA; Bischoff LA; Jessop AC; Sobel RK
Endocr Pract; 2022 Dec; 28(12):1210-1215. PubMed ID: 35970353
[TBL] [Abstract][Full Text] [Related]
15. Epiphora after radioactive iodine therapy in a low-risk patient.
Song H; Jeong J; Ju Koh M
Clin Nucl Med; 2015 Jun; 40(6):536-7. PubMed ID: 25674875
[TBL] [Abstract][Full Text] [Related]
16. Iodine-131 Therapy and Nasolacrimal Duct Obstructions: What We Know and What We Need to Know.
Ali MJ
Ophthalmic Plast Reconstr Surg; 2016; 32(4):243-8. PubMed ID: 26866333
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Demographic Characteristics of Tearing in Patients after Radioiodine Ablation for Differentiated Thyroid Cancer.
Yartsev VD; Solodkiy VA; Fomin DK; Borisenko TE; Atkova EL
Curr Eye Res; 2021 Sep; 46(9):1320-1324. PubMed ID: 33455422
[No Abstract] [Full Text] [Related]
18. Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy.
Liang C; Wu C; Liu L; Zhong J
Int Ophthalmol; 2024 Jun; 44(1):257. PubMed ID: 38909080
[TBL] [Abstract][Full Text] [Related]
19. Lacrimal System Obstruction After Radioiodine Therapy in Differentiated Thyroid Carcinomas: A Prospective Comparative Study.
da Fonseca FL; Yamanaka PK; Kato JM; Matayoshi S
Thyroid; 2016 Dec; 26(12):1761-1767. PubMed ID: 27565021
[TBL] [Abstract][Full Text] [Related]
20. Accumulation of 131Iodine in the nasolacrimal sac/duct after radioiodine therapy for papillary thyroid cancer.
Usmani S; Jain A; Al-Riyami K; Abubakar S
J Pak Med Assoc; 2023 Mar; 73(3):713-714. PubMed ID: 36932793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]